General Anxiety Disorder

Neurology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
GABITRILPhase 31 trial
Active Trials
NCT00233675Completed
Engrail Therapeutics
Engrail TherapeuticsCA - San Diego
1 program
1
ENX-102Phase 21 trial
Active Trials
NCT06653296Completed38Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaGABITRIL
Engrail TherapeuticsENX-102

Clinical Trials (2)

Total enrollment: 38 patients across 2 trials

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

Start: Aug 2003
Phase 3Completed

A Dose-Response Safety Study of ENX-102 in Patients With GAD

Start: Dec 2024Est. completion: Jun 202538 patients
Phase 2Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space